Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Pricing Debate Elections Policy

Trump’s Drug Pricing Remarks: A Gambit For Industry Self-Restraint?

  • Analysis

Executive Summary

Comments during recent interview shows president-elect continues to view drug pricing as populist issue, revives speculation he may take action to control prices.

You may also be interested in...



Who's Promised What: A Guide To Pharma Drug Pricing Pledges

Have pharma companies responded sufficiently to President Trump's call for “massive” price reductions?

Just Trust Me: Most Firms Unwilling To Publicly Pledge Pricing Restraint

Public Citizen reached out to the 28 largest biopharma manufacturers after Allergan announced its pricing pledge to see who else might follow suit. The answer was, not many.

Carrots and Stick: Biopharma At The White House

Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Scrip
Scrip

Topics

Related Companies

Tags:
Pricing Debate Elections Policy
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS119638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By